SG Americas Securities LLC Has $2.72 Million Stock Position in Syndax Pharmaceuticals, Inc. $SNDX

SG Americas Securities LLC raised its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 184.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 129,227 shares of the company’s stock after buying an additional 83,801 shares during the period. SG Americas Securities LLC owned about 0.15% of Syndax Pharmaceuticals worth $2,715,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in SNDX. Larson Financial Group LLC increased its holdings in shares of Syndax Pharmaceuticals by 192.2% during the 3rd quarter. Larson Financial Group LLC now owns 2,922 shares of the company’s stock worth $45,000 after acquiring an additional 1,922 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Syndax Pharmaceuticals during the 3rd quarter valued at $53,000. Lazard Asset Management LLC acquired a new stake in Syndax Pharmaceuticals during the 2nd quarter valued at $66,000. Tower Research Capital LLC TRC boosted its position in Syndax Pharmaceuticals by 103.3% during the second quarter. Tower Research Capital LLC TRC now owns 8,480 shares of the company’s stock worth $79,000 after purchasing an additional 4,308 shares during the period. Finally, Prudential Financial Inc. acquired a new position in shares of Syndax Pharmaceuticals in the second quarter valued at $97,000.

Syndax Pharmaceuticals Stock Performance

Shares of SNDX stock opened at $25.15 on Friday. The stock’s fifty day moving average price is $22.16 and its two-hundred day moving average price is $19.35. The company has a market cap of $2.22 billion, a PE ratio of -7.64 and a beta of 0.41. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $8.58 and a fifty-two week high of $25.59. The company has a debt-to-equity ratio of 5.32, a quick ratio of 4.12 and a current ratio of 4.40.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.14). The business had revenue of $68.73 million during the quarter, compared to analyst estimates of $64.75 million. Syndax Pharmaceuticals had a negative net margin of 165.37% and a negative return on equity of 206.62%. The business’s quarterly revenue was up 792.6% compared to the same quarter last year. During the same period last year, the business earned ($1.10) earnings per share. Equities analysts predict that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Keith A. Goldan sold 3,410 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $21.03, for a total transaction of $71,712.30. Following the completion of the transaction, the chief financial officer directly owned 140,429 shares in the company, valued at $2,953,221.87. This trade represents a 2.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael A. Metzger sold 17,159 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $21.03, for a total transaction of $360,853.77. Following the transaction, the chief executive officer owned 491,690 shares of the company’s stock, valued at approximately $10,340,240.70. The trade was a 3.37% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 30,063 shares of company stock valued at $628,332. 4.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages recently commented on SNDX. The Goldman Sachs Group upped their price target on shares of Syndax Pharmaceuticals from $28.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday. JPMorgan Chase & Co. boosted their price objective on Syndax Pharmaceuticals from $33.00 to $45.00 and gave the stock an “overweight” rating in a report on Monday, March 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a research report on Friday, March 27th. Citigroup increased their target price on Syndax Pharmaceuticals from $51.00 to $57.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Finally, Jefferies Financial Group reissued a “buy” rating and set a $40.00 price target (down from $48.00) on shares of Syndax Pharmaceuticals in a report on Monday, March 30th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Syndax Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.33.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.